Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Total Current Liabilities (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Total Current Liabilities for 5 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 67.66% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, down 67.66%, while the annual FY2025 figure was $6.6 million, 67.66% down from the prior year.
  • Total Current Liabilities hit $6.6 million in Q4 2025 for Kezar Life Sciences, down from $13.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $20.4 million in Q3 2024 and bottomed at $5.9 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $12.6 million, with a median of $13.5 million recorded in 2023.
  • Year-over-year, Total Current Liabilities skyrocketed 95.53% in 2023 and then plummeted 67.66% in 2025.
  • Kezar Life Sciences' Total Current Liabilities stood at $8.2 million in 2021, then surged by 33.91% to $11.0 million in 2022, then soared by 61.35% to $17.7 million in 2023, then increased by 14.57% to $20.3 million in 2024, then tumbled by 67.66% to $6.6 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $6.6 million, $13.4 million, and $14.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.